论文部分内容阅读
目的探讨阿托伐他汀联合曲美他嗪治疗冠心病心绞痛的临床疗效。方法选取南通市通州区人民医院2015年4月—2016年4月收治的冠心病心绞痛患者78例,随机分为对照组和研究组,各39例。对照组患者给予盐酸曲美他嗪片治疗,研究组在对照组基础上给予阿托伐他汀治疗,两组患者均持续治疗2周。比较两组患者心电图疗效、心绞痛症状改善效果,治疗前后心绞痛发作次数及发作持续时间,观察患者不良反应发生情况。结果研究组患者心电图临床疗效,心绞痛改善效果优于对照组(P<0.05)。治疗前,两组患者心绞痛发作次数及发作持续时间比较,差异无统计学意义(P>0.05);治疗后,研究组患者心绞痛发作次数少于对照组,发作持续时间短于对照组(P<0.05)。两组患者均未出现严重不良反应。结论阿托伐他汀联合曲美他嗪治疗冠心病心绞痛的临床疗效确切,可有效改善患者心功能及心绞痛症状,且安全性好。
Objective To investigate the clinical efficacy of atorvastatin combined with trimetazidine in the treatment of angina pectoris of coronary heart disease. Methods Totally 78 patients with coronary heart disease and angina pectoris admitted from April 2015 to April 2016 in Tongzhou District People’s Hospital of Nantong were randomly divided into control group and study group, with 39 cases in each group. Patients in the control group were treated with trimetazidine hydrochloride. The study group was given atorvastatin on the basis of the control group, and both groups were treated for 2 weeks. The electrocardiogram curative effect, the improvement effect of angina pectoris, the frequency of angina pectoris and the duration of seizure before and after treatment were compared between the two groups, and the incidence of adverse reactions was observed. Results The clinical efficacy of ECG and the improvement of angina in study group were better than those in control group (P <0.05). Before treatment, there was no significant difference between the two groups in the number of angina attacks and the duration of attack (P> 0.05). After treatment, the number of angina attacks in study group was less than that in control group, and the duration of attack was shorter than that in control group (P < 0.05). No serious adverse reactions occurred in both groups. Conclusion Atorvastatin combined with trimetazidine treatment of coronary heart disease angina pectoris clinical efficacy is exact, can effectively improve the patient’s cardiac function and angina pectoris, and good safety.